RESUMO
OBJECTIVE: To explore the association between miR-1298 expression and clinicopathological factors, prognosis of gastric cancer (GC) patients and biological functions underlying the GC progression. PATIENTS AND METHODS: Expression of miR-1298 was examined by qRT-PCR in GC tissues and cells, the adjacent normal tissues and normal gastric cell line GES-1 cells were used as controls. Association of disease-free survival (DFS) and overall survival (OS) time with miR-1298 expression was analyzed by Kaplan-Meier analysis and log-rank test. Univariate and multivariate analysis were also performed to analyze relative prognostic risk factors of GC patients. Cell proliferation and invasion assays were used to examine cell proliferation and invasion capacities in vitro. The relative protein expression was analyzed by Western blot analysis. RESULTS: MiR-1298 expression was lower in GC tissues and cells, compared to adjacent normal tissues and GES-1 cells, respectively. Lower miR-1298 expression levels were associated with lymph node metastasis and TNM stage. Kaplan-Meier analysis showed that lower miR-1298 expression predicted poor DFS and OS of GC patients. Furthermore, we demonstrated that lymph node metastasis, TNM stage, and lower miR-1298 expression were independent risk factors for DFS and OS in GC patients. In vitro, miR-1298 overexpression inhibited cell proliferation and invasion abilities. Additionally, our results revealed that miR-1298 overexpression suppressed PI3K/AKT signaling pathway in GC cells. CONCLUSIONS: Our evidence indicated that miR-1298 may provide a specifically promising target for therapy of GC patients.